Optimizing therapy for del(17p) multiple myeloma von Avet-Loiseau, Hervé, Richardson, Paul G, di Bacco, Alessandra

Volltext

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma von Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid

Volltext

p53 expression in K562 cells is associated with caspase‐mediated cleavage of c‐ABL and BCR–ABL protein kinases von Di Bacco, Alessandra M. A., Cotter, Thomas G.

Volltext

The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate insulin-like growth factor II receptor von Di Bacco, Alessandra, Gill, Grace

Volltext

SUMO-Specific Proteases and the Cell Cycle von Di Bacco, Alessandra, Gill, Grace

Volltext

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients von Richardson, Paul G., Baz, Rachid, Wang, Michael, Jakubowiak, Andrzej J., Laubach, Jacob P., Harvey, R. Donald, Talpaz, Moshe, Berg, Deborah, Liu, Guohui, Yu, Jiang, Gupta, Neeraj, Di Bacco, Alessandra, Hui, Ai-Min, Lonial, Sagar

Volltext

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an ope... von Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

Volltext

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients von Avet-Loiseau, Hervé, Bahlis, Nizar J., Chng, Wee-Joo, Masszi, Tamas, Viterbo, Luisa, Pour, Ludek, Ganly, Peter, Palumbo, Antonio, Cavo, Michele, Langer, Christian, Pluta, Andrzej, Nagler, Arnon, Kumar, Shaji, Ben-Yehuda, Dina, Rajkumar, S. Vincent, San-Miguel, Jesus, Berg, Deborah, Lin, Jianchang, van de Velde, Helgi, Esseltine, Dixie-Lee, di Bacco, Alessandra, Moreau, Philippe, Richardson, Paul G.

Volltext

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival von KUNII, Kaiko, DAVIS, Lenora, GORENSTEIN, Julie, HATCH, Harold, YASHIRO, Masakazu, DI BACCO, Alessandra, ELBI, Cem, LUTTERBACH, Bart

Volltext

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy von Mulligan, George, Lichter, David I., Di Bacco, Alessandra, Blakemore, Stephen J., Berger, Allison, Koenig, Erik, Bernard, Hugues, Trepicchio, William, Li, Bin, Neuwirth, Rachel, Chattopadhyay, Nibedita, Bolen, Joseph B., Dorner, Andrew J., van de Velde, Helgi, Ricci, Deborah, Jagannath, Sundar, Berenson, James R., Richardson, Paul G., Stadtmauer, Edward A., Orlowski, Robert Z., Lonial, Sagar, Anderson, Kenneth C., Sonneveld, Pieter, San Miguel, Jesús F., Esseltine, Dixie-Lee, Schu, Matthew

Volltext

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications von Anderson, Kenneth C, Auclair, Daniel, Kelloff, Gary J, Sigman, Caroline C, Avet-Loiseau, Hervé, Farrell, Ann T, Gormley, Nicole J, Kumar, Shaji K, Landgren, Ola, Munshi, Nikhil C, Cavo, Michele, Davies, Faith E, Di Bacco, Alessandra, Dickey, Jennifer S, Gutman, Steven I, Higley, Howard R, Hussein, Mohamad A, Jessup, J Milburn, Kirsch, Ilan R, Little, Richard F, Loberg, Robert D, Lohr, Jens G, Mukundan, Lata, Omel, James L, Pugh, Trevor J, Reaman, Gregory H, Robbins, Michael D, Sasser, A Kate, Valente, Nancy, Zamagni, Elena

Volltext

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple... von Mateos, María-Victoria, Masszi, Tamas, Grzasko, Norbert, Hansson, Markus, Sandhu, Irwindeep, Pour, Ludek, Viterbo, Luísa, Jackson, Sharon R, Stoppa, Anne-Marie, Gimsing, Peter, Hamadani, Mehdi, Borsaru, Gabriela, Berg, Deborah, Lin, Jianchang, Di Bacco, Alessandra, van de Velde, Helgi, Richardson, Paul G, Moreau, Philippe

Volltext

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma von Moreau, Philippe, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J., Hansson, Markus, Pour, Ludek, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W., Jackson, Sharon R., Stoppa, Anne-Marie, Simpson, David R., Gimsing, Peter, Palumbo, Antonio, Garderet, Laurent, Cavo, Michele, Kumar, Shaji, Touzeau, Cyrille, Buadi, Francis K., Laubach, Jacob P., Berg, Deborah T., Lin, Jianchang, Di Bacco, Alessandra, Hui, Ai-Min, van de Velde, Helgi, Richardson, Paul G.

Volltext

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation von Dash, Ajeeta B., Zhang, Jacob, Shen, Lei, Li, Bin, Berg, Deborah, Lin, Jianchang, Avet‐Loiseau, Hervé, Bahlis, Nizar J., Moreau, Philippe, Richardson, Paul G., Di Bacco, Alessandra

Volltext

The SUMO-Specific Protease SENP5 Is Required for Cell Division von Di Bacco, Alessandra, Ouyang, Jian, Lee, Hsiang-Ying, Catic, Andre, Ploegh, Hidde, Gill, Grace

Volltext

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagn... von San-Miguel, Jesús F, Echeveste Gutierrez, Maria-Asunción, Špicka, Ivan, Mateos, María-Victoria, Song, Kevin, Craig, Michael D, Bladé, Joan, Hájek, Roman, Chen, Christine, Di Bacco, Alessandra, Estevam, Jose, Gupta, Neeraj, Byrne, Catriona, Lu, Vickie, van de Velde, Helgi, Lonial, Sagar

Volltext

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma von Di Bacco, Alessandra, Bahlis, Nizar J., Munshi, Nikhil C., Avet‐Loiseau, Hervé, Masszi, Tamás, Viterbo, Luísa, Pour, Ludek, Ganly, Peter, Cavo, Michele, Langer, Christian, Kumar, Shaji K., Rajkumar, S. Vincent, Keats, Jonathan J., Berg, Deborah, Lin, Jianchang, Li, Bin, Badola, Sunita, Shen, Lei, Zhang, Jacob, Esseltine, Dixie‐Lee, Luptakova, Katarina, Velde, Helgi, Richardson, Paul G., Moreau, Philippe

Volltext

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models von Ellwood-Yen, Katharine, Keilhack, Heike, Kunii, Kaiko, Dolinski, Brian, Connor, Yamicia, Hu, Kun, Nagashima, Kumiko, O'Hare, Erin, Erkul, Yusuf, Di Bacco, Alessandra, Gargano, Diana, Shomer, Nirah H, Angagaw, Minilik, Leccese, Erica, Andrade, Paula, Hurd, Melissa, Shin, Myung K, Vogt, Thomas F, Northrup, Alan, Bobkova, Ekaterina V, Kasibhatla, Shailaja, Bronson, Roderick T, Scott, Martin L, Draetta, Giulio, Richon, Victoria, Kohl, Nancy, Blume-Jensen, Peter, Andersen, Jannik N, Kraus, Manfred

Volltext

The Crystal Structure of CREG, a Secreted Glycoprotein Involved in Cellular Growth and Differentiation von Sacher, Michael, Alessandra Di Bacco, Vladimir V. Lunin, Zheng Ye, Wagner, John, Gill, Grace, Cygler, Miroslaw, Matthews, Brian W.

Volltext

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma von Moreau, Philippe, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J, Hansson, Markus, Pour, Ludek, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W, Jackson, Sharon R, Stoppa, Anne-Marie, Simpson, David R, Gimsing, Peter, Palumbo, Antonio, Garderet, Laurent, Cavo, Michele, Kumar, Shaji, Touzeau, Cyrille, Buadi, Francis K, Laubach, Jacob P, Berg, Deborah T, Lin, Jianchang, Di Bacco, Alessandra, Hui, Ai-Min, van de Velde, Helgi, Richardson, Paul G

Volltext